on 14 Feb 2025
Last Applicant/ Owned by
Guangzhou Decheng Biotechnology Co., LTD
Room 218, Building 2, No.68, Nanxiang RoadScience City, Huangpu District510000, Guangzhou,
CN
Serial Number
2165117 filed on 9th Feb 2022
Correspondent Address
PIASETZKI NENNIGER KVAS LLP
SUITE 2308120 ADELAIDE STREET WESTTORONTO
ONTARIO
CA
M5H1T1
Trademark usage description
diagnostic biomarker reagents for medical purposes; chemical diagnostic reagents for medical or veterinary purposes; chemical preparations for the dia Read MoreVienna Information
2 . 7 . 9
Woman (women) and baby (babies)Femme(s) et bébé(s)
2 . 7 . 23
Groups stylized, shadows or silhouettes of groups -- Note: Including groups of stick figures.Groupes stylisés, ombres ou silhouettes de groupes -- Note: Y compris les groupes de bonshommes-allumettes.
2 . 3 . 16
Shadows or silhouettes of womenOmbres ou silhouettes de femmes
2 . 3 . 23
Women stylized -- Note: Including stick figures of women.Femmes stylisées -- Note: Y compris les bonshommes-allumettes de femmes.
2 . 3 . 30
Other womenAutres femmes
27 . 5 . 1
Letters presenting a special form of writingLettres présentant un graphisme spécial
27 . 5 . 8
Letters linked to or containing a figurative element -- Note: Letters representing a human being or a part of the human body, an animal or a part of an animal's body, a plant, a heavenly body, a natural phenomenon or an object are classified in division 27.3.Lettres liées à un élément figuratif ou contenant un élément figuratif -- Note: Les lettres représentant un être humain ou une partie du corps humain, un animal ou une partie du corps d'un animal, un végétal, un corps céleste, un phénomène naturel ou un objet sont classées dans la division 27.3.
CIPO Classification Code
Nice
11
11
2165117
Trademark
Action Taken | Status |
---|---|
Submitted for opposition 20 on 18th Feb 2025 | Examiner's First Report |
Submitted for opposition 22 on 14th Feb 2025 | Search Recorded |
Submitted for opposition 287 on 18th May 2022 | Pre-Assessment Letter Sent |
Submitted for opposition 30 on 9th Feb 2022 | Filed |
Submitted for opposition 1 on 9th Feb 2022 | Created |
Submitted for opposition 31 on 9th Feb 2022 | Formalized |